UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation ...

Exhibit 99.1 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results SAN DIEGO, May 8, 2025 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided recent business updates. ® "Coinciding with the end of the 2024-2025 flu season in the Northern Hemisphere, we have es ...

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology ...

Cidara Therapeutics (CDTX) 2025 Conference May 07, 2025 11:00 AM ET Speaker0 Alright. Thank you everybody again for joining us, Citizens Life Science Conference here. We, next company we have is Sadara Therapeutics, and we have Jeff Stein is president and CEO and a co founder. Frank Carbe, CFO, was going to be here, had some travel related issues, but we're happy to have Jeff here to walk us through the Sadara story. Pretty exciting few weeks coming up definitely with a phase two b breed out at the June. So ...

Group 1 - The company Cidara Therapeutics (NASDAQ: CDTX) is initiating coverage with a Strong Buy rating, indicating a positive outlook for the stock [1] - Cidara has shifted its focus from antifungal treatments to its proprietary Cloudbreak drug Fc conjugate platform, suggesting a strategic pivot in its business model [1]

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025. “These promotions come at a pivotal time as we continue advancing our influenza antiviral candidate, ...

Group 1: Company Overview - Cidara Therapeutics (CDTX) currently has a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Group 2: Performance Metrics - CDTX shares have increased by 10.8% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 6.19% [5] - Over the past month, CDTX's price change is 11.63%, compared to the industry's 2.23% [5] - In the last quarter, CDTX shares increased by 5.39%, and over the past year, they have gained 76.29%, while the S&P 500 has moved -7.64% and 10.16% respectively [6] Group 3: Trading Volume - The average 20-day trading volume for CDTX is 162,652 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 4: Earnings Outlook - In the past two months, one earnings estimate for CDTX has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$14.39 to -$7.12 [9] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [9] Group 5: Conclusion - Considering all performance metrics and earnings outlook, CDTX is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/jmp65/cdtx/1686102 A replay of the prese ...

Core Insights - Phathom Pharmaceuticals has appointed Ted Schroeder to its Board of Directors, which is seen as a strategic move during a critical time for the company [1][3]. Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases, including the first-in-class potassium-competitive acid blocker (PCAB) vonoprazan, marketed as VOQUEZNA® [7]. Leadership Experience - Ted Schroeder brings over 30 years of experience in the biopharmaceutical industry, having held leadership roles in various companies and successfully guiding them through significant milestones and transactions [2][4]. - His previous roles include CEO of Nabriva Therapeutics and co-founder of Cadence Pharmaceuticals, which was acquired for $1.4 billion [4]. Strategic Importance - The appointment of Schroeder is expected to enhance Phathom's operational and commercial capabilities, particularly as the company aims to accelerate its commercial momentum and deliver innovative therapies to patients [3][5].

Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Needham representative directly. About Cidara Therapeutics Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to ach ...